IMPL insider filings

IMPEL PHARMACEUTICALS INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-12-19. Screen IMPL transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for IMPL between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — IMPEL PHARMACEUTICALS INC

FiledFormInsiderReported transactionsSource
2023-12-194Vivo Capital VIII, LLC — 10% owner
Vivo Capital Fund VIII, L.P. — 10% owner
Vivo Capital Surplus Fund VIII, L.P. — 10% owner
Sale (S): 87,934 @ $0.29 · Sale (S): 12,066 @ $0.29 · Sale (S): 209,029 @ $0.11 · Sale (S): 28,682 @ $0.11 · Sale (S): 208,657 @ $0.08 · Sale (S): 28,632 @ $0.08EDGAR
2023-12-044Oaktree-TCDRS Strategic Credit, LLC — 10% owner
Oaktree-Forrest Multi-Strategy,LLC — 10% owner
Oaktree-TBMR Strategic Credit Fund C, LLC — 10% owner
Oaktree-TBMR Strategic Credit Fund F, LLC — 10% owner
Oaktree-TBMR Strategic Credit Fund G, LLC — 10% owner
Oaktree-TSE 16 Strategic Credit, LLC — 10% owner
INPRS Strategic Credit Holdings, LLC — 10% owner
Oaktree Gilead Investment Fund AIF (Delaware), L.P. — 10% owner
Oaktree Specialty Lending Corp — 10% owner
Oaktree Strategic Credit Fund — 10% owner
Other (J): 445,294 (derivative)EDGAR
2023-12-044Oaktree GCP Fund Delaware Holdings, L.P. — 10% owner
Oaktree Diversified Income Fund Inc. — 10% owner
Oaktree AZ Strategic Lending Fund, L.P. — 10% owner
Oaktree Loan Acquisition Fund, L.P. — 10% owner
Oaktree LSL Fund Holdings EURRC S.a.r.l. — 10% owner
Oaktree LSL Fund Delaware Holdings EURRC, L.P. — 10% owner
Oaktree PRE Life Sciences Fund, L.P. — 10% owner
Oaktree Capital Group, LLC — 10% owner
Atlas OCM Holdings, LLC — 10% owner
Other (J): 445,294 (derivative)EDGAR
2023-12-044BROOKFIELD Corp /ON/ — 10% owner
BAM Partners Trust — 10% owner
Brookfield Asset Management ULC — 10% owner
Other (J): 445,294 (derivative)EDGAR
2023-06-204Cline Darren S — DirectorGrant/award (A): 13,222 (derivative) @ $0EDGAR
2023-06-204Allison David D. — DirectorGrant/award (A): 13,222 (derivative) @ $0EDGAR
2023-06-204Wilfong Diane E. — DirectorGrant/award (A): 13,222 (derivative) @ $0EDGAR
2023-06-204SHAH MAHENDRA — DirectorGrant/award (A): 13,222 (derivative) @ $0EDGAR
2023-06-204NELSON TIMOTHY S — DirectorGrant/award (A): 13,222 (derivative) @ $0EDGAR
2023-05-124Kalb Michael Wayne — CFOGrant/award (A): 175,000 (derivative) @ $0 · Grant/award (A): 47,500 (derivative) @ $0EDGAR
2023-04-144Cline Darren S — DirectorGrant/award (A): 20,013 (derivative) @ $0EDGAR
2023-02-164Paolillo Leonard — Chief Commercial OfficerGrant/award (A): 50,000 (derivative) @ $0EDGAR
2023-02-164Hoekman John — Chief Scientific OfficerGrant/award (A): 42,500 (derivative) @ $0EDGAR
2023-02-164Leaman John Harold — Chief Fin. & Business OfficerGrant/award (A): 70,000 (derivative) @ $0EDGAR
2023-02-164ADAMS ADRIAN — COB, CEO and President, DirectorGrant/award (A): 200,000 (derivative) @ $0EDGAR
2023-01-044Leaman John Harold — Chief Fin. & Business OfficerOption exercise (M): 10,571 @ $0 · Tax withholding (F): 3,627 @ $3.75 · Option exercise (M): 10,571 (derivative) @ $0EDGAR
2022-06-174Allison David D. — DirectorGrant/award (A): 12,789 (derivative) @ $0EDGAR
2022-06-174Wilfong Diane E. — DirectorGrant/award (A): 12,789 (derivative) @ $0EDGAR
2022-06-174SHAH MAHENDRA — DirectorGrant/award (A): 12,789 (derivative) @ $0EDGAR
2022-06-174NELSON TIMOTHY S — DirectorGrant/award (A): 12,789 (derivative) @ $0EDGAR
2022-06-174PARKER H STEWART — DirectorGrant/award (A): 12,789 (derivative) @ $0EDGAR
2022-03-304SHREWSBURY STEPHEN B — Chief Medical OfficerOption exercise (M): 24,606 @ $1.97 · Option exercise (M): 24,606 (derivative) @ $0EDGAR
2022-01-284Paolillo Leonard — Chief Commercial OfficerGrant/award (A): 40,000 (derivative) @ $0EDGAR
2022-01-284Leaman John Harold — Chief Fin. & Business OfficerGrant/award (A): 100,000 (derivative) @ $0EDGAR
2022-01-284Hoekman John — Chief Scientific OfficerGrant/award (A): 35,000 (derivative) @ $0EDGAR
2022-01-284SHREWSBURY STEPHEN B — Chief Medical OfficerGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-01-284ADAMS ADRIAN — COB, CEO and President, DirectorGrant/award (A): 175,000 (derivative) @ $0EDGAR
2021-12-234Hoekman John — Chief Scientific OfficerOption exercise (M): 20,000 @ $1.64 · Option exercise (M): 20,000 (derivative) @ $0EDGAR
2021-11-224NELSON TIMOTHY S — DirectorPurchase (P): 10,000 @ $10.76EDGAR
2021-10-214Leaman John Harold — Chief Fin. & Business OfficerGrant/award (A): 10,571 (derivative) @ $0EDGAR
2021-09-224SHREWSBURY STEPHEN B — Chief Medical OfficerOption exercise (M): 14,780 @ $1.97 · Option exercise (M): 4,650 @ $2.46 · Option exercise (M): 53,954 @ $2.95 · Option exercise (M): 14,780 (derivative) @ $0 · Option exercise (M): 4,650 (derivative) @ $0 · Option exercise (M): 53,954 (derivative) @ $0EDGAR
2021-08-194ADAMS ADRIAN — COB, CEO and President, DirectorPurchase (P): 17,203 @ $13.81 · Purchase (P): 2,197 @ $14.91 · Purchase (P): 600 @ $15.89EDGAR
2021-07-264Paolillo Leonard — Chief Commercial OfficerGrant/award (A): 30,000 (derivative) @ $0EDGAR
2021-07-264Leaman John Harold — Chief Financial OfficerGrant/award (A): 50,000 (derivative) @ $0EDGAR
2021-07-264Hoekman John — Chief Scientific OfficerGrant/award (A): 50,000 (derivative) @ $0EDGAR
2021-07-264SHREWSBURY STEPHEN B — Chief Medical OfficerGrant/award (A): 50,000 (derivative) @ $0EDGAR
2021-07-264ADAMS ADRIAN — COB, CEO and President, DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2021-07-134Allison David D. — DirectorGrant/award (A): 11,500 (derivative) @ $0EDGAR
2021-07-134Wilfong Diane E. — DirectorGrant/award (A): 11,500 (derivative) @ $0EDGAR
2021-07-134SHAH MAHENDRA — DirectorGrant/award (A): 11,500 (derivative) @ $0EDGAR
2021-07-134NELSON TIMOTHY S — DirectorGrant/award (A): 11,500 (derivative) @ $0EDGAR
2021-07-134PARKER H STEWART — DirectorGrant/award (A): 11,500 (derivative) @ $0EDGAR
2021-06-224/APARKER H STEWART — DirectorHoldings only — no transactions reportedEDGAR
2021-06-074/AHoekman John — Chief Scientific OfficerConversion (C): 4,253 @ $0 · Conversion (C): 69,657 (derivative) @ $0EDGAR
2021-04-294Hoekman John — Chief Scientific OfficerConversion (C): 4,523 · Other (J): 275 @ $0 · Option exercise/expiry (X): 8,523 (derivative) @ $8.19 · Option exercise/expiry (X): 8,523 (derivative) @ $0 · Conversion (C): 69,657 (derivative) @ $0EDGAR
2021-04-294venBio Global Strategic Fund II L.P. — 10% owner
venBio Global Strategic GP II, L.P. — 10% owner
venBio Global Strategic GP II, Ltd. — 10% owner
GOODMAN COREY S — 10% owner
Adelman Robert J — 10% owner
Conversion (C): 2,309,791 · Purchase (P): 450,000 @ $15 · Conversion (C): 5,876,034 (derivative) @ $0 · Conversion (C): 8,201,930 (derivative) @ $0 · Conversion (C): 8,845,942 (derivative) @ $0 · Conversion (C): 13,233,885 (derivative) @ $0 · +1 moreEDGAR
2021-04-2945AM Ventures V, L.P. — 10% owner
5AM Partners V, LLC — 10% owner
PARMAR KUSH — 10% owner
ROCKLAGE SCOTT M — 10% owner
Schwab Andrew J. — 10% owner
5AM Opportunities I, L.P. — 10% owner
5AM Opportunities I (GP), LLC — 10% owner
Conversion (C): 808,259 · Conversion (C): 540,265 · Conversion (C): 500,932 · Conversion (C): 358,878 · Conversion (C): 101,457 @ $13.50 · Purchase (P): 575,000 @ $15 · +5 moreEDGAR
2021-04-294PARKER H STEWART — DirectorConversion (C): 3,732 · Conversion (C): 7,355 · Other (J): 458 @ $0 · Conversion (C): 8,793 · Other (J): 1,666 @ $0 · Conversion (C): 271 @ $13.50 · +8 moreEDGAR
2021-04-294Norwest Venture Partners XIV, LP — 10% owner
Crowe Jeffrey — 10% owner
HAQUE PROMOD — 10% owner
Kossow Jon Erik — 10% owner
Conversion (C): 98,927 @ $13.50 · Conversion (C): 2,153,271 @ $0 · Purchase (P): 825,000 @ $15 · Conversion (C) @ $0 · Conversion (C): 35,256,206 (derivative) @ $0EDGAR
2021-04-294KKR Iris Investors LLC — 10% owner
KKR Healthcare Strategic Growth Fund L.P. — 10% owner
KKR Associates HCSG L.P. — 10% owner
KKR HCSG GP LLC — 10% owner
KKR Group Partnership L.P. — 10% owner
KKR Group Holdings Corp. — 10% owner
KKR & Co. Inc. — 10% owner
KKR Management LLP — 10% owner
KRAVIS HENRY R — 10% owner
ROBERTS GEORGE R — 10% owner
Conversion (C): 2,583,926 · Other (J): 118,712 @ $13.50 · Purchase (P): 1,100,000 @ $15 · Conversion (C): 42,307,448 (derivative)EDGAR

Recent 8-K events — IMPEL PHARMACEUTICALS INC

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-03-128-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2024-02-148-K1.01 — Entry into a Material Definitive Agreement
1.03 — Bankruptcy or Receivership
2.01 — Completion of Acquisition or Disposition of Assets
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
EDGAR
2024-01-028-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-12-208-K1.01 — Entry into a Material Definitive Agreement
1.03 — Bankruptcy or Receivership
2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-12-188-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-12-048-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-11-148-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2023-11-028-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-10-168-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-10-048-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=IMPL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs